Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
ProQR Therapeutics NV
13G
PRQR · N71542109
|
6.3% |
7/29/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 6.3% | ||||
| abrdn Inc. | 6.3% | ||||
|
Eloxx Pharmaceuticals Inc
13G
ELOX · 29014R103
|
9.9% |
7/27/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 9.9% | ||||
| abrdn Inc. | 9.9% | ||||
|
uniQure N.V.
13G/A
Amendment 4
QURE · N90064101
|
4.5% |
7/20/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 4.5% | ||||
| abrdn Inc. | 4.5% | ||||
|
Codexis, Inc.
13G/A
Amendment 3
CDXS · 192005106
|
7.5% |
7/20/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 7.5% | ||||
| abrdn Inc. | 7.5% | ||||
|
Immunic, Inc.
13G/A
Amendment 2
IMUX · 4525EP200
|
6.1% |
7/16/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 6.1% | ||||
| abrdn Inc. | 6.1% | ||||
|
Sera Prognostics, Inc.
13G/A
Amendment 1
SERA · 81749D107
|
7.2% |
7/15/2026
Event 6/30/2026
|
|||
| Aberdeen Group plc | 7.2% | ||||
| abrdn Inc. | 7.2% | ||||
|
Equillium, Inc.
13G
EQ · 29446K106
|
5.3% |
5/7/2026
Event 4/1/2026
|
|||
| Aberdeen Group plc | 5.3% | ||||
| abrdn Inc. | 5.3% | ||||
|
uniQure N.V.
13G/A
Amendment 3
QURE · N90064101
|
8.5% |
4/30/2026
Event 4/1/2026
|
|||
| Aberdeen Group plc | 8.5% | ||||
| abrdn Inc. | 8.5% | ||||
|
Quoin Pharmaceuticals, Ltd.
13G/A
Amendment 1
QNRX · 74907L409
|
4.2% |
4/29/2026
Event 4/1/2026
|
|||
| Aberdeen Group plc | 4.2% | ||||
| abrdn Inc. | 4.2% | ||||
|
Perceptive Capital Solutions Corp
13G
PCSC · G70077105
|
6.5% |
4/28/2026
Event 4/1/2026
|
|||
| Aberdeen Group plc | 6.5% | ||||
| abrdn Inc. | 6.5% | ||||
|
InspireMD, Inc.
13G/A
Amendment 1
NSPR · 45779A846
|
7.5% |
2/2/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 7.5% | ||||
| abrdn Inc. | 7.5% | ||||
|
Immunic, Inc.
13G/A
Amendment 1
IMUX · 4525EP101
|
6.9% |
2/2/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 6.9% | ||||
| abrdn Inc. | 6.9% | ||||
|
uniQure N.V.
13G/A
Amendment 2
QURE · N90064101
|
5.9% |
1/29/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 5.9% | ||||
| abrdn Inc. | 5.9% | ||||
|
Tectonic Therapeutic, Inc.
13G
TECX · 878972108
|
6.1% |
1/29/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 6.1% | ||||
| abrdn Inc | 6.1% | ||||
|
Quoin Pharmaceuticals, Ltd.
13G
QNRX · 74907L409
|
8.9% |
1/28/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 8.9% | ||||
| abrdn Inc. | 8.9% | ||||
|
Precision Biosciences Inc
13G
DTIL · 74019P207
|
8.9% |
1/27/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 8.9% | ||||
| abrdn Inc. | 8.9% | ||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G
CRBP · 21833P301
|
7.5% |
1/16/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 7.5% | ||||
| abrdn Inc. | 7.5% | ||||
|
Codexis, Inc.
13G/A
Amendment 2
CDXS · 192005106
|
8.8% |
1/15/2026
Event 12/31/2025
|
|||
| Aberdeen Group plc | 8.8% | ||||
| abrdn Inc. | 8.8% | ||||
|
Codexis, Inc.
13G/A
Amendment 1
CDXS · 192005106
|
4.5% |
11/7/2025
Event 10/1/2025
|
|||
| Aberdeen Group plc | 4.5% | ||||
| abrdn Inc. | 4.5% | ||||
|
InspireMD, Inc.
13G
NSPR · 45779A846
|
6.0% |
11/7/2025
Event 10/1/2025
|
|||
| Aberdeen Group plc | 6.0% | ||||
| abrdn Inc. | 6.0% | ||||
|
uniQure N.V.
13G/A
Amendment 1
QURE · N90064101
|
4.8% |
10/14/2025
Event 9/30/2025
|
|||
| Aberdeen Group plc | 4.8% | ||||
| abrdn Inc. | 4.8% | ||||
|
Sera Prognostics, Inc.
13G
SERA · 81749D107
|
6.1% |
8/5/2025
Event 6/30/2025
|
|||
| Aberdeen Group plc | 6.1% | ||||
| abrdn Inc. | 6.1% | ||||
|
Immunic, Inc
13G
IMUX · 4525EP101
|
8.6% |
7/31/2025
Event 6/30/2025
|
|||
| Aberdeen Group plc | 8.6% | ||||
| abrdn Inc | 8.6% | ||||
|
uniQure N.V.
13G
QURE · N90064101
|
5.0% |
7/31/2025
Event 6/30/2025
|
|||
| Aberdeen Group plc | 5.0% | ||||
| abrdn Inc. | 5.0% | ||||
|
Codexis, Inc.
13G
CDXS · 192005106
|
5.1% |
7/30/2025
Event 6/30/2025
|
|||
| Aberdeen Group plc | 5.1% | ||||
| abrdn Inc. | 5.1% | ||||